Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.

Journal: Technology in cancer research & treatment
Published Date: Dec 5, 2017

Abstract

INTRODUCTION: Whole-gland salvage treatment of radiorecurrent prostate cancer has a high rate of severe toxicity. The standard of care in case of a biochemical recurrence is androgen deprivation treatment, which is associated with morbidity and negative effects on quality of life. A salvage treatment with acceptable toxicity might postpone the start of androgen deprivation treatment, might have a positive influence on the patients' quality of life, and might even be curative. Here, toxicity and biochemical outcome are described after magnetic resonance imaging-guided focal salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer.

Authors

  • Metha Maenhout
    1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Max Peters
    1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Marco van Vulpen
    2 Department of Urology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Marinus A Moerland
    1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Richard P Meijer
    1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Maurice A A J van den Bosch
    1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Paul L Nguyen
    Department of Radiation Oncology, Dana-Farber/Brigham Cancer Center, Boston.
  • Steven J Frank
    4 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jochem R N van der Voort van Zyp
    1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.

Keywords

External Resources

Popular Topics
Recent Journals